I-O Therapy in mCRC: Ipilimumab + Nivolumab

Transcript:

Johanna C. Bendell, MD: For patients with microsatellite instable [MSI] colorectal cancer, we have seen benefits of immunotherapy. We do have multiple FDA approvals for these patients of agents, including pembrolizumab, nivolumab, and now nivolumab plus ipilimumab. We see single-agent response rates in the range of 30% to 50% for patients with PD-1 inhibitors, and we also know that patients who respond to these PD-1 inhibitors tend to have very prolonged responses.

The CheckMate-142 study looked both at single-agent nivolumab and nivolumab plus ipilimumab. The 2 arms weren